DailySpaceMetro Healthcare Berhad
0329 · ACE Market创业板（ACE Market） · annual reports 2024 to 2025, 513 entries read2024 至 2025 年报，共读出 513 条
The company这家公司
Metro Healthcare Berhad provides obstetrics and gynaecology healthcare services and assisted reproductive technology services in Malaysia. Its history lists the establishment of Tee Maternity and Gynae Specialist Center in 1989, and the start of intrauterine insemination and in vitro fertilisation procedures in 1998.Metro Healthcare Berhad 在马来西亚提供妇产科医疗服务及辅助生殖技术服务。公司沿革列出 1989 年成立 Tee Maternity and Gynae Specialist Center，并于 1998 年开始提供宫腔内人工授精与试管婴儿疗程。
Source: annual report 2024, pages 7, 83.出处：2024 年年报第 7、83 页。
The company was listed on the LEAP Market of Bursa Securities in 2018, and on the ACE Market of Bursa Securities on 15 November 2024.公司于 2018 年在马来西亚证券交易所 LEAP 市场上市，并于 2024 年 11 月 15 日在创业板（ACE Market）上市。
Source: annual report 2024, pages 7, 8, 48.出处：2024 年年报第 7、8、48 页。
All revenue is generated in Malaysia. In 2025, outpatient services generated RM22,986,267, ambulatory care generated RM22,604,950, and inpatient services generated RM4,824,376. The group does not have significant reliance on a single major customer transacting 10% or more of its revenue.全部营业额均来自马来西亚。2025 年，门诊服务产生 RM22,986,267，日间医疗照护产生 RM22,604,950，住院服务产生 RM4,824,376。集团对交易额占其营业额 10% 或以上的单一主要客户不存在重大依赖。
Source: annual report 2024, page 83; annual report 2025, pages 71, 74.出处：2024 年年报第 83 页；2025 年年报第 71、74 页。
Executive Vice Chairman Dr. Tay Swi Peng @ Tee Swi Peng holds 378,643,728 shares (38.68%) and an indirect interest in 49,385,536 shares (5.05%); Country Range Sdn. Bhd. holds 49,385,536 shares (5.05%). A total of 378,171,328 shares (38.63%) are in a pledged securities account under Maybank Nominees (Tempatan) Sdn. Bhd. for Dr. Tay. His spouse, director Dr. Kong Lan Moon, holds 190,801,640 shares (19.49%). Director Lim Wai Khong is the brother-in-law of Dr. Kong Lan Moon.执行副主席 Dr. Tay Swi Peng @ Tee Swi Peng 持有 378,643,728 股（38.68%），另间接持有 49,385,536 股（5.05%）；Country Range Sdn. Bhd. 持有 49,385,536 股（5.05%）。Maybank Nominees (Tempatan) Sdn. Bhd. 为 Dr. Tay 开立的抵押证券账户持有 378,171,328 股（38.63%）。他的配偶、董事 Dr. Kong Lan Moon 持有 190,801,640 股（19.49%）。董事 Lim Wai Khong 是 Dr. Kong Lan Moon 的姻亲兄弟。
Source: annual report 2025, pages 30, 79, 80.出处：2025 年年报第 30、79、80 页。
On 28 February 2024, Dr. Tay Swi Peng @ Tee Swi Peng was redesignated from Executive Chairman to Executive Vice Chairman, and Pn. Rose Zilawati binti Mohamed Arifin, Ms. Chua Leng Leek and Dr. Yee Meng Kheong were appointed to the Board. External auditors HLB Ler Lum Chew PLT indicated they would not seek re-appointment at the 16th AGM.2024 年 2 月 28 日，Dr. Tay Swi Peng @ Tee Swi Peng 由执行主席调任为执行副主席，Pn. Rose Zilawati binti Mohamed Arifin、Ms. Chua Leng Leek 与 Dr. Yee Meng Kheong 获委任加入董事会。外聘审计师 HLB Ler Lum Chew PLT 表示不在第 16 届股东周年大会上寻求连任。
Source: annual report 2024, pages 19, 20, 22, 23; annual report 2025, pages 52, 81, 84.出处：2024 年年报第 19、20、22、23 页；2025 年年报第 52、81、84 页。
Revenue by service type, 20252025 年各服务类别营业额
Source: annual report 2025, page 71.出处：2025 年年报第 71 页。
Major events大事记
Source: annual report 2024, pages 19, 20, 22, 23.出处：2024 年年报第 19、20、22、23 页。
Source: annual report 2024, page 50.出处：2024 年年报第 50 页。
Source: annual report 2024, pages 48, 50.出处：2024 年年报第 48、50 页。
Source: annual report 2025, page 12.出处：2025 年年报第 12 页。
Source: annual report 2025, pages 12, 48.出处：2025 年年报第 12、48 页。
Source: annual report 2025, page 6.出处：2025 年年报第 6 页。
Source: annual report 2025, pages 6, 12.出处：2025 年年报第 6、12 页。
Source: annual report 2025, pages 52, 81, 84.出处：2025 年年报第 52、81、84 页。
Revenue, profit before taxation and operating cash营业额、税前盈利与营运现金
Total assets, total equity and cash总资产、总权益与现金
20242024 年
In conjunction with its listing on the ACE Market on 15 November 2024, the company issued 156,625,000 new shares at RM0.25 each, raising gross proceeds of RM39,156,250, with net proceeds from share capital of RM38,124,099. A bonus issue of 205,570,000 new shares was completed on 8 October 2024. Net cash generated from operating activities was RM9,994,897. Acquisition of property, plant and equipment took RM4,418,303. Dividends paid were RM4,440,312, and repayment of lease liabilities used RM2,451,320. Total cash and cash equivalents ended at RM51,406,599.配合 2024 年 11 月 15 日在创业板上市，公司以每股 RM0.25 发行 156,625,000 股新股，募集总资金 RM39,156,250，扣除费用后股本所得款项净额为 RM38,124,099。2024 年 10 月 8 日完成发行 205,570,000 股红股。营运活动所得现金净额为 RM9,994,897。购买物业、厂房及设备支出 RM4,418,303。已付股息 RM4,440,312，偿还租赁负债使用 RM2,451,320。现金及现金等价物期末达 RM51,406,599。
Source: annual report 2024, pages 48, 50, 63, 64.出处：2024 年年报第 48、50、63、64 页。
20252025 年
Net cash generated from operating activities was RM9,070,582. Two interim dividends totalling RM6,362,882, comprising 0.40 sen and 0.25 sen per share, were paid. Acquisition of property, plant and equipment took RM1,478,327, and repayment of lease liabilities used RM2,545,637.营运活动所得现金净额为 RM9,070,582。全年派发两笔中期股息共 RM6,362,882，分别为每股 0.40 仙和 0.25 仙。购买物业、厂房及设备支出 RM1,478,327，偿还租赁负债使用 RM2,545,637。
Source: annual report 2025, pages 50, 59, 73.出处：2025 年年报第 50、59、73 页。
Across the years历年合看
Across the two years, net cash generated from operating activities was RM9,994,897 in 2024 and RM9,070,582 in 2025. Acquisition of property, plant and equipment took RM4,418,303 in 2024 and RM1,478,327 in 2025. Dividends paid were RM4,440,312 in 2024 and RM6,362,882 in 2025. Repayments of lease liabilities took RM2,451,320 in 2024 and RM2,545,637 in 2025.两年合看，营运活动所得现金净额在 2024 年为 RM9,994,897，2025 年为 RM9,070,582。购买物业、厂房及设备支出在 2024 年为 RM4,418,303，2025 年为 RM1,478,327。已付股息在 2024 年为 RM4,440,312，2025 年为 RM6,362,882。偿还租赁负债在 2024 年使用 RM2,451,320，2025 年使用 RM2,545,637。
Source: annual report 2024, pages 63, 64; annual report 2025, page 59.出处：2024 年年报第 63、64 页；2025 年年报第 59 页。
Still to be spent尚未支出的承诺
From the initial public offering raising gross proceeds of RM39.156 million, unutilised proceeds were RM33.9 million at end-2024 and RM24.8 million at end-2025, including RM15.5 million for expansion of the existing O&G business and RM9.3 million for expansion of healthcare-related business. Capital commitments contracted but not provided for were RM222,732 at end-2024 and RM1,029,000 at end-2025.在首次公开募股所筹集的 RM39.156 million 资金中，2024 年底未动用款项为 RM33.9 million，2025 年底为 RM24.8 million，其中包括用于扩充现有妇产科业务的 RM15.5 million 与扩充医疗相关业务的 RM9.3 million。已签约但未拨备的资本承诺在 2024 年底为 RM222,732，2025 年底为 RM1,029,000。
Source: annual report 2024, pages 48, 93; annual report 2025, pages 48, 76.出处：2024 年年报第 48、93 页；2025 年年报第 48、76 页。
Four years of figures四年数字
Group figures, in RM, as printed in the statements.集团数字，单位令吉，照财务报表所印。
| Group集团 | 2023 | 2024 | 2025 |
|---|---|---|---|
| RM令吉 | RM令吉 | RM令吉 | |
| Revenue营业额 | 44,686,028 | 48,649,823 | 50,415,593 |
| Profit before taxation税前盈利 | 8,542,443 | 7,172,325 | 8,169,498 |
| Net cash generated from operating activities营运活动所得现金净额 | 10,934,925 | 9,994,897 | 9,070,582 |
| Acquisition of property, plant and equipment购买物业、厂房及设备 | (3,551,107) | (4,418,303) | (1,478,327) |
| Dividend paid已付股息 | (4,316,970) | (4,440,312) | (6,362,882) |
| Net cash (used in)/generated from investing activities投资活动（所用）/所得现金净额 | (3,342,331) | (4,979,245) | (938,843) |
| Net cash generated from/(used in) financing activities融资活动所得/（所用）现金净额 | (6,719,630) | 31,232,467 | (8,908,519) |
| Cash and cash equivalents现金及现金等价物 | 15,158,480 | 51,406,599 | 50,629,819 |
| Total assets总资产 | 59,778,230 | 96,032,352 | 92,524,988 |
| Total liabilities总负债 | 22,402,945 | 20,413,838 | 17,407,711 |
| Total equity总权益 | 37,375,285 | 75,618,514 | 75,117,277 |
On a computer, hover over a figure for the report and page it is printed on.在电脑上把鼠标移到数字上，可看到它印在哪份年报的哪一页。
Said and done说过的与做到的
| What the reports said年报说要做的 | What later reports show之后年报显示的 | Status状态 |
|---|---|---|
| To actively explore mergers and acquisitions of maternity hospitals in the Klang Valley and other regions of Peninsular Malaysia积极探索巴生谷及西马其他地区妇产医院的兼并与收购 | On 23 October 2025 the company agreed to buy 100.0% of RMC Specialist Sdn. Bhd. from Dr. Tay Swi Peng @ Tee Swi Peng for RM320,000.00; RMC Specialist is developing a 120-bedded multi-disciplinary hospital at Bandar Rimbayu, Selangor, and the acquisition was completed on 10 March 2026.公司于 2025 年 10 月 23 日同意以 RM320,000.00 向 Dr. Tay Swi Peng @ Tee Swi Peng 收购 RMC Specialist Sdn. Bhd. 全部股权；RMC Specialist 正在雪兰莪 Bandar Rimbayu 发展一家 120 床综合医院，收购于 2026 年 3 月 10 日完成。 Source: annual report 2024, page 15; annual report 2025, pages 5, 12.出处：2024 年年报第 15 页；2025 年年报第 5、12 页。 | Hospital project bought from a director; not an existing maternity hospital向董事收购医院项目；并非现有妇产医院 |
| Renovation of a facility in Kelantan, for which capital expenditure commitments of RM0.22 million were reported翻新吉兰丹的医疗设施，已呈报资本支出承诺 RM0.22 million | The group opened its seventh IVF centre, in Kota Bharu, Kelantan, in 2025. The report does not say this is the facility the renovation commitment was for.集团于 2025 年在吉兰丹哥打巴鲁开设第七间试管婴儿中心。年报没有说这就是该装修承诺所指的设施。 Source: annual report 2024, page 13; annual report 2025, pages 6, 11.出处：2024 年年报第 13 页；2025 年年报第 6、11 页。 | Kota Bharu centre opened哥打巴鲁中心已开业 |
What the reports leave open年报留下待看的事
- Development of the 120-bedded multi-disciplinary hospital in Bandar Rimbayu, Selangor under RMC Specialist Sdn. Bhd., which is expected to commence operation in Q2 2028.RMC Specialist Sdn. Bhd. 在雪兰莪 Bandar Rimbayu 发展的 120 床综合医院，预计于 2028 年第二季度投入运作。
Source: annual report 2025, pages 5, 12.出处：2025 年年报第 5、12 页。
- Deployment of RM24.8 million in remaining listing proceeds within the 36-month timeframe, comprising RM15.5 million for O&G business expansion and RM9.3 million for healthcare-related business.在 36 个月期限内动用剩余的 RM24.8 million 上市所得款项，其中包括用于妇产科业务扩充的 RM15.5 million 与用于医疗相关业务的 RM9.3 million。
Source: annual report 2025, page 48.出处：2025 年年报第 48 页。
- Appointment of new external auditors following the decision of HLB Ler Lum Chew PLT not to seek re-appointment at the 16th AGM.在 HLB Ler Lum Chew PLT 决定不在第 16 届股东周年大会上寻求连任后，委任新外聘审计师的事宜。
Source: annual report 2025, pages 52, 81, 84.出处：2025 年年报第 52、81、84 页。
- Capital commitments contracted but not provided for, which stood at RM1,029,000 at end-2025 compared with RM222,732 at end-2024.已签约但未拨备的资本承诺，从 2024 年底的 RM222,732 增至 2025 年底的 RM1,029,000。
Source: annual report 2024, page 93; annual report 2025, page 76.出处：2024 年年报第 93 页；2025 年年报第 76 页。
Facts as printed in the company's annual reports, with the page of each; no rating and no advice. Built 2026-10-28.内容为公司年报所印的事实，并注明页码；不评级，不构成投资建议。生成日期 2026-10-28。